HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Augmentation of antitumor effect by combined administration with interleukin-2 and sizofiran, a single glucan, on murine EL-4 lymphoma.

Abstract
The antitumor effect of the combined administration with recombinant human interleukin-2 (rIL-2) and sizofiran (SPG), a single glucan of Shizophyllum commune Fries, was studied in vivo in C57BL/6 mice intraperitoneally inoculated with EL-4 lymphoma. The effect was evaluated by a) comparing the survival time of the mice, b) analysis of the intraperitoneal cell population in Giemsa-stained specimens, c) surface marker analysis of peritoneal exudative cells with flow cytometry, d) cytotoxic assay of cells against EL-4 and Yac-1 lymphoma, and e) elimination of some cell populations by monoclonal antibodies, to identify the antitumor-effector cells showing cytotoxic activity. The survival of mice given both rIL-2 and SPG was significantly longer than the control mice or those given SPG alone or rIL-2 alone. It was demonstrated that the administration of SPG and/or rIL-2 to the EL-4 lymphoma-bearing mice activated immune-response cells in the peritoneal cavity such as T lymphocytes, NK cells, or macrophages, which might be effective in reducing lymphoma cells. The combination of rIL-2 and SPG administration appears to activate the antitumor-immune response at the tumor site more effectively than when either agent was administered alone.
AuthorsY Kano, H Kakuta, J Hashimoto
JournalBiotherapy (Dordrecht, Netherlands) (Biotherapy) Vol. 9 Issue 4 Pg. 241-7 ( 1996) ISSN: 0921-299X [Print] Netherlands
PMID9012543 (Publication Type: Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Interleukin-2
  • Recombinant Proteins
  • Sizofiran
Topics
  • Animals
  • Antibodies, Monoclonal (immunology)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Cytotoxicity, Immunologic
  • Flow Cytometry
  • Humans
  • Interleukin-2 (administration & dosage)
  • Lymphoma (immunology, mortality, therapy)
  • Mice
  • Mice, Inbred C57BL
  • Recombinant Proteins (administration & dosage)
  • Sizofiran (administration & dosage)
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: